Study of Nivolumab in combination with ipilimumab or standard of care chemotherapy compared to the standard of care chemotherapy

Skip to Content

Clinical Trial Details

CA209-901

Study of Nivolumab in combination with ipilimumab or standard of care chemotherapy compared to the standard of care chemotherapy alone in treatment of patients with untreated inoperable or metastatic urothelial cancer.

Objective

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating patients with previously untreated inoperable or metastatic urothelial cancer.

NCT# 03036098

Clinical Trial Categories

  • Bladder Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6031